Cormorant Asset Management »

Tourmaline Bio shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Tourmaline Bio (TRML) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Tourmaline Bio

Tip: Access up to 7 years of quarterly data

All positions including Tourmaline Bio held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tourmaline Bio by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $29M 1.3M 22.90

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Eyepoint Pharmaceuticals Com New (EYPT)
Arcellx Common Stock (ACLX)
Alpine Immune Sciences (ALPN)
Bridgebio Pharma (BBIO)
Praxis Precision Medicines I Com New (PRAX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Tarsus Pharmaceuticals (TARS)
Longboard Pharmaceuticals In (LBPH)
Edgewise Therapeutics (EWTX)
Crinetics Pharmaceuticals In (CRNX)
Biomea Fusion (BMEA)
Korro Bio (KRRO)
Vaxcyte (PCVX)
Autolus Therapeutics Spon Ads (AUTL)

View all positions for Cormorant Asset Management

Top funds holding Tourmaline Bio

Blue Owl Capital Holdings
Cormorant Asset Management
Jennison Associates
QVT Financial
Vanguard Group
Braidwell
venBio Select Advisor
Nantahala Capital Management
Qiming U.S. Ventures Management
Vivo Capital
BlackRock
Darwin Global Management
Eventide Asset Management
Velan Capital Investment Management
Artal Group

View all funds holding Tourmaline Bio